The Cigna Group (CI) Stock Forecast & Price Target

$301.27 +1.59 (+0.53%)

As of 12:03 PM Eastern

The Cigna Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 17 Analyst Ratings

Sell
0

Hold
2

Buy
15

Based on 17 Wall Street analysts who have issued ratings for The Cigna Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 17 analysts, 2 have given a hold rating, 13 have given a buy rating, and 2 have given a strong buy rating for CI.

Consensus Price Target

$373.69
24.04% Upside

According to the 17 analysts' twelve-month price targets for The Cigna Group, the average price target is $373.69. The highest price target for CI is $438.00, while the lowest price target for CI is $323.00. The average price target represents a forecasted upside of 24.04% from the current price of $301.27.

Get the Latest News and Ratings for CI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for The Cigna Group and its competitors.

CI Analyst Ratings Over Time

Type	Current Forecast 2/22/24 to 2/21/25	1 Month Ago 1/23/24 to 1/22/25	3 Months Ago 11/24/23 to 11/23/24	1 Year Ago 2/22/23 to 2/22/24
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$373.69	$395.93	$394.64	$357.15
Forecasted Upside	24.04% Upside	36.98% Upside	20.15% Upside	4.41% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

CI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

The Cigna Group Stock vs. The Competition

Type	The Cigna Group	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.64% Upside	29,063.41% Upside	12.83% Upside
News Sentiment Rating	Positive News See Recent CI News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/6/2025	Sanford C. Bernstein 3 of 5 stars	L. Wilkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$323.00	+10.24%
2/4/2025	Truist Financial 2 of 5 stars	David Macdonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$390.00 ➝ $375.00	+28.20%
2/4/2025	Wells Fargo & Company 3 of 5 stars	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$370.00 ➝ $341.00	+16.46%
2/3/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$410.00 ➝ $390.00	+31.64%
2/3/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jessica Tassan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$394.00 ➝ $348.00	+18.13%
1/31/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	John Ransom Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$415.00 ➝ $360.00	+21.26%
1/31/2025	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Wiederhorn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$400.00 ➝ $375.00	+26.31%
1/31/2025	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Raj Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$410.00 ➝ $380.00	+28.89%
1/31/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$400.00 ➝ $350.00	+17.99%
1/31/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$403.00 ➝ $379.00	+34.20%
Get the Latest News and Ratings for CI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for The Cigna Group and its competitors with MarketBeat's FREE daily newsletter.
1/31/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$420.00 ➝ $339.00	+20.03%
11/4/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$398.00 ➝ $394.00	+25.93%
11/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$384.00 ➝ $377.00	+19.61%
9/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$402.00 ➝ $422.00	+16.25%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$435.00 ➝ $438.00	+27.49%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$388.00	+16.54%
2/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$360.00 ➝ $370.00	+14.41%
8/17/2023	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
8/4/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$320.00 ➝ $350.00	+21.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:04 PM ET.

Should I Buy The Cigna Group Stock? CI Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, February 16, 2025. Please send any questions or comments about these The Cigna Group pros and cons to contact@marketbeat.com.

The Cigna Group
Bull Case

Here are some ways that investors could benefit from investing in The Cigna Group:

The Cigna Group has a strong average rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for stock appreciation.
The company recently increased its quarterly dividend to $1.51 per share, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend yield of approximately 2.07%, which can provide a steady income stream for investors.
Current stock price is $292.12, which is significantly lower than the consensus target price of $373.69, suggesting potential upside for investors looking to buy at a discount.
The Cigna Group has a solid market capitalization of approximately $81.25 billion, indicating a stable and established presence in the insurance and health services sector.
Despite a recent earnings miss, the company reported a return on equity of 18.61%, showcasing effective management and profitability, which can be attractive to investors seeking growth.

The Cigna Group
Bear Case

Investors should be bearish about investing in The Cigna Group for these reasons:

The Cigna Group's recent earnings report showed a miss on consensus estimates, with earnings per share of $6.64 compared to the expected $7.84, which may raise concerns about future profitability.
The stock has experienced volatility, with a 1-year low of $262.03, indicating potential risks associated with price fluctuations that could affect investor returns.
The company's net margin of 1.39% is relatively low, suggesting that profitability may be constrained, which could impact future growth and dividend payments.
Analysts have recently adjusted their price targets downward, with several firms reducing their targets significantly, which may indicate a lack of confidence in the stock's near-term performance.
The Cigna Group has a debt-to-equity ratio of 0.70, which, while manageable, indicates that the company is using a moderate amount of debt to finance its operations, potentially increasing financial risk in a rising interest rate environment.

CI Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for The Cigna Group is $373.69, with a high forecast of $438.00 and a low forecast of $323.00.
: 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Cigna Group in the last year. There are currently 2 hold ratings, 13 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CI shares.
: According to analysts, The Cigna Group's stock has a predicted upside of 24.04% based on their 12-month stock forecasts.
: Over the previous 90 days, The Cigna Group's stock had 1 downgrade by analysts.
: The Cigna Group has been rated by research analysts at Barclays, Cantor Fitzgerald, Morgan Stanley, Oppenheimer, Piper Sandler, Raymond James, Sanford C. Bernstein, Stephens, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like The Cigna Group more than other "medical" companies. The consensus rating for The Cigna Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CI compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:CI) was last updated on 2/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The Cigna Group (CI) Stock Forecast & Price Target